BioLargo, Inc.
23461 South Pointe Drive
Suite 200
Laguna Hills
California
92653
United States
16 articles with BioLargo, Inc.
-
BioLargo Revenue Continues Breaking Records as Water Technologies Ready for Commercialization
11/16/2020
BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, filed with the SEC its Quarterly Report on Form 10-Q for the period ended September 30, 2020 ( www.biolargo.com/sec-filings ). BioLargos Third Quarter Accomplishments Record revenue - generated record revenues in the third quarter, rebounding from early pandemic shutdowns
-
BioLargo Awarded Contract for Engineering Services at Major Chemical Manufacturing Facility
10/21/2020
BioLargo, Inc, announced today that its subsidiary BioLargo Engineering, Science & Technologies (BLEST) has been awarded a contract to assist in the reconfiguration of the Regenerative Thermal Oxidizer (RTO) systems used at a large chemical manufacturing plant on the East Coast of the US, owned by a global chemical company,
-
BioLargo Subsidiary Clyra Medical’s Clyraguard Product Shows Complete Inactivation of SARS-CoV-2 Virus in Galveston National Lab Study
5/21/2020
BioLargo, Inc. announced that Clyraguard, the product developed by its partially owned subsidiary Clyra Medical Technologies in response to the COVID-19 pandemic has been successfully shown to cause complete inactivation of the SARS-CoV-2 virus in laboratory testing.
-
Dennis Calvert, CEO of BioLargo, Inc., Returns to Uptick Newswire’s Stock Day Podcast to Discuss the Company’s Record-Breaking Quarterly Results and a Progress Report on its March to its First Industry-Wide Adoption
8/16/2018
Dennis Calvert, CEO of BioLargo, Inc. (OTCQB: BLGO) recently spoke with “Stock Day” host Everett Jolly about BioLargo’s progress since the previous show at the end of July.
-
BioLargo, Inc.'s Medical Subsidiary Files 510(K) With FDA For Its Novel Wound Care Technology
9/28/2017
-
BioLargo, Inc. Secures Financing For Its Advanced Wound Care Products Targeting FDA Application, Approval And Commercialization Through Its Subsidiary Clyra Medical Technologies
1/8/2016
-
BioLargo, Inc. Issued Patent For Its Platform Of Liquid And Hydrogel Iodine Technologies
11/13/2014
-
BioLargo, Inc. Granted Additional Patent As It Lands Second Order From US Government
11/18/2013
-
BioLargo, Inc. Achieves Breakout Milestones in Advanced Wound Care on Track for FDA 510(k) Submission and Commercialization
12/17/2012
-
BioLargo, Inc. Adds Wound Management Expert and Former VP at Smith & Nephew Inc., Tanya Rhodes, to Its Team
8/6/2012
-
BioLargo, Inc. Forms Medical Products Subsidiary to Focus on Advanced Wound Care
5/15/2012
-
BioLargo, Inc. Granted Key Patents
9/29/2011
-
BioLargo, Inc. Adds Key Medical Industry Executive - Tim R. Johnson
8/24/2011
-
BioLargo, Inc. Adds Water Expert and Former Pepsi-Cola International VP-Technical Services -- Harry DeLonge to Its Team
2/24/2011
-
BioLargo, Inc. Enters into Marketing Agreement for Leading Iodine Disinfection Technology
8/25/2008
-
NuWay Medical, Inc. Changes Name to BioLargo, Inc.; Announces Reverse Stock Split, Recapitalization, and Conversion of Debt and Payables to Equity
3/22/2007